Biodesix, Inc. (NASDAQ:BDSX) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Biodesix, Inc. (NASDAQ:BDSX) have received a consensus recommendation of “Moderate Buy” from the six brokerages that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $32.50.

Several equities analysts have recently weighed in on BDSX shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Biodesix in a research report on Monday, December 22nd. Wall Street Zen raised Biodesix from a “sell” rating to a “hold” rating in a report on Saturday, November 8th.

Institutional Trading of Biodesix

Hedge funds and other institutional investors have recently bought and sold shares of the company. XTX Topco Ltd boosted its holdings in Biodesix by 99.4% in the 2nd quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock valued at $58,000 after purchasing an additional 102,494 shares during the period. Millennium Management LLC purchased a new stake in shares of Biodesix in the third quarter worth $113,000. Oracle Investment Management Inc. bought a new stake in Biodesix during the third quarter valued at $113,000. Finally, Aberdeen Group plc purchased a new position in Biodesix during the fourth quarter worth about $1,784,000. Institutional investors own 20.96% of the company’s stock.

Biodesix Price Performance

BDSX opened at $11.10 on Friday. The firm has a 50-day moving average price of $7.55 and a 200-day moving average price of $7.60. Biodesix has a twelve month low of $3.44 and a twelve month high of $21.80. The company has a quick ratio of 1.84, a current ratio of 1.84 and a debt-to-equity ratio of 41.11. The company has a market capitalization of $88.36 million, a price-to-earnings ratio of -2.00 and a beta of 0.60.

Biodesix (NASDAQ:BDSX) last released its quarterly earnings data on Monday, November 3rd. The company reported ($1.16) EPS for the quarter, topping the consensus estimate of ($1.60) by $0.44. Biodesix had a negative net margin of 49.31% and a negative return on equity of 504.41%. The company had revenue of $21.77 million during the quarter, compared to the consensus estimate of $20.98 million. Equities analysts expect that Biodesix will post -0.35 EPS for the current year.

About Biodesix

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.